Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tiziana Life Sciences Ltd (TLSA : NSDQ)

• Company Description    Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $1.48 Daily Weekly Monthly 20 Day Moving Average: 210,940 shares Shares Outstanding: 127.26 (millions) Market Capitalization: $188.34 (millions) Beta: 0.42 52 Week High: $2.60 52 Week Low: $1.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.33% 14.45% 12 Week 1.37% -6.29% Year To Date -0.67% -9.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 14-15 CONDUIT STREET - LONDON,X0 W1S 2XJ GBR ph: 44-20-7495-2379 fax: - ikoffler@lifesciadvisors.com http://www.tizianalifesciences.com

• General Corporate Information    Officers Ivor Elrifi - Chief Executive Officer Gabriele Marco Antonio Cerrone - Executive Chairman Keeren Shah - Chief Operating and Financial Officer John Brancaccio - Director Willy Simon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G88912103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 08/07/26 Share - Related Items Shares Outstanding: 127.26 Most Recent Split Date: 7.00 (2.50:1) Beta: 0.42 Market Capitalization: $188.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3,621.95 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - - 12/31/25 - - 09/30/25 - - Current Ratio 03/31/26 - - 12/31/25 - 0.76 09/30/25 - - Quick Ratio 03/31/26 - - 12/31/25 - 0.76 09/30/25 - - Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - - 12/31/25 - 0.00 09/30/25 - - Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 0.00 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - 0.00 09/30/25 - -

Powered by Zacks Investment Research ©